Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
A Parallel Group Study in Healthy Participants to Quantitate Increases in Subclinical Gastrointestinal Blood Loss Following Administration of Aspirin Alone or in Combination With Rivaroxaban or Factor XI Inhibitors (REGN9933 or REGN7508)
Sponsor: Regeneron Pharmaceuticals
A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 2 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .